KRAS and non-small cell lung carcinoma: Regarding OS, NSCLC patients harboring KRAS G12/G13-mutant cfDNA exhibited a significantly (p < 0.001) inferior OS compared with patients in the KRAS G12/G13-wild type cfDNA group (Figure 1).